Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$407.90 USD
-4.32 (-1.05%)
Updated Oct 15, 2025 04:00 PM ET
After-Market: $407.10 -0.80 (-0.20%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Vertex Pharmaceuticals Incorporated has a market cap of $105.69B, which represents its share price of $412.22 multiplied by its outstanding shares number of 256.39M. As a large-cap company, VRTX's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VRTX 407.90 -4.32(-1.05%)
Will VRTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Other News for VRTX
VRTX's price rises by 1.19% on October 14, though its technical setup remains stable.
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
VRTX forms Non-ADX 1,2,3,4 Bullish on October 13
Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo
Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)